Accelerated development of fast and reliable COVID-19 test

/in /by

Leading Dutch biochip companies accelerate development of fast and reliable COVID-19 test.

April 23, 2020

Surfix B.V., together with its shareholders Qurin Diagnostics B.V. and LioniX International B.V., already successfully developing bio-photonic nanochips for cancer detection and other applications, today announce an accelerated development plan to allow mass-scale COVID-19 diagnosis and immunity detection with the financial support and in close collaboration with PhotonDelta.

The desktop testing device will yield reliable test results within 5 minutes and is scheduled to be available for commercial exploitation within 6-9 months. The device will be built around a photonic biochip using LioniX’ mature and proven silicon nitride based integrated optics technology (TriPleX™), a key technology within the PhotonDelta ecosystem. The surface functionalization and biochemical assay development are provided by Surfix and Qurin Diagnostics, respectively. The combination of these disciplines enables a successful, fast and accurate virus detection platform. The development will be supported by and in tight collaboration with Photon Delta (a Dutch public private partnership). The PhotonDelta support will be both in co-funding as in further future upscaling and exploitation.

Read Press release LioniX – Qurin – SurfiX – PD.

LioniX International appoints Arne Leinse as new CEO

/in /by

On December 3, 2019 LioniX International has appointed Arne Leinse as the new CEO as of January 1st 2020. LioniX International is the leading global provider of customized microsystem solutions, in particular integrated photonics-based, in scalable production volumes.

Read more

Leading Dutch alliance in biochip development

/in /by

As of April 15, 2019, Qurin Diagnostics B.V. and Lionix International B.V. have acquired Surfix B.V. As a supplier of custom-made nanocoatings, the capabilities of Surfix are highly complementary to the products and services offered by Qurin and LioniX International. The companies are already working together closely on early cancer detection and have realized a sensitive biochip, bringing together their respective complementary technologies for this purpose. This acquisition strengthens their relationship and mutual commitment towards bringing this technology to the global biomedical market. Read the complete press release

PHIX Photonics Assembly secures next round of financing and LioniX International obtains a majority share.

/in /by

Tuesday, July 10, 2018: PHIX Photonics assembly (PHIX) moves forward in the next step of its growth due to the recent acquisition of LioniX International BV by Magic Micro Co. Ltd . As part of this acquisition and the further implementation plan towards high volume assembly of Photonic Integrated Circuit (PIC)  modules, LioniX International has increased its share in PHIX. This will strengthen its position as a vertical integrated supplier of PIC based modules.

In parallel to this change in ownership, PHIX also secures financial support for the upscaling from semi- automated to fully-automated assembly lines. Both Magic Micro and Panthera International (the original main shareholder of LioniX International) are committing to financially support PHIX for further upscaling. This growth is needed to serve current customers and market demands.

Read more

For more information contact Dr.  Joost van Kerkhof (j.vankerkhof@phix-pa.com)

Magic Micro acquires majority share in LioniX International

/in /by

Magic Micro, a Kosdaq-listed South Korean electronic component company, has acquired a majority share of 75% in LioniX International. This acquisition between two complementary companies strengthens the position of both and clearly shows the Photonic Integrated Circuit (PIC) based ecosystem is further maturing.

Read the press release.